(Q31899349)

4 July 2017

A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma (English)

1 reference

4 July 2017

Niitsu N

1

1 reference

PubMed ID

11168504

4 July 2017

Iijima K

series ordinal

2

1 reference

PubMed ID

11168504

4 July 2017

Chizuka A

series ordinal

3

1 reference

4 July 2017

1 January 2001

1 reference

European Journal of Haematology

4 July 2017

1 reference

4 July 2017

66

1 reference

4 July 2017

1

1 reference

4 July 2017

24-30

1 reference

T cell growth factor receptors. Quantitation, specificity, and biological relevance

4 July 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

Serum soluble interleukin-2 receptor levels in patients with adult T-cell leukemia and human T-cell leukemia/lymphoma virus type-I seropositive healthy carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

The soluble interleukin-2 receptor: biology, function, and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

Individual Comparisons by Ranking Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

7 January 2021

Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

7 January 2021

Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

7 January 2021

COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

7 January 2021

Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

7 January 2021

Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00334.X

7 January 2021

10.1034/J.1600-0609.2001.00334.X

Identifiers

DOI

1 reference

4 July 2017

1 reference

PubMed ID

11168504